Aduro BioTech Inc. announced on January 30, 2019, that it would be cutting its headcount by around 37%, shelving some of its pipeline programs and focusing all its resources on the discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation inducing ligand (APRIL) pathways.
As a result of this company reset and the subsequent reduction in ongoing operating expenses, Aduro expects to extend its...